1. Home
  2. NEWT vs CLLS Comparison

NEWT vs CLLS Comparison

Compare NEWT & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NewtekOne Inc.

NEWT

NewtekOne Inc.

HOLD

Current Price

$13.75

Market Cap

400.6M

Sector

Finance

ML Signal

HOLD

Logo Cellectis S.A.

CLLS

Cellectis S.A.

HOLD

Current Price

$3.16

Market Cap

394.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NEWT
CLLS
Founded
1998
1999
Country
United States
France
Employees
572
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
400.6M
394.4M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
NEWT
CLLS
Price
$13.75
$3.16
Analyst Decision
Buy
Strong Buy
Analyst Count
3
3
Target Price
$15.33
$8.33
AVG Volume (30 Days)
125.0K
30.6K
Earning Date
04-30-2026
05-08-2026
Dividend Yield
6.00%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$12.45
$0.98
P/E Ratio
$5.99
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.59
$1.33
52 Week High
$14.91
$5.48

Technical Indicators

Market Signals
Indicator
NEWT
CLLS
Relative Strength Index (RSI) 56.86 39.24
Support Level $12.56 $3.05
Resistance Level $14.21 $3.35
Average True Range (ATR) 0.42 0.17
MACD -0.02 -0.04
Stochastic Oscillator 74.06 32.25

Price Performance

Historical Comparison
NEWT
CLLS

About NEWT NewtekOne Inc.

NewtekOne Inc provides business and financial solutions under the Newtek and NewtekOne brands to the independent business owner (SMB) market. Its services are offered online and in some cases delivered by staff via video and voice calls. The company offers lending products, FDIC insured deposit products and services, payments processing, payroll services and insurance brokerage services. Loan products include SBA 7(a), ALP, SBA 504, and traditional C&I and CRE bank loans, while deposit products include consumer high yield savings accounts, high yield certificates of deposit, zero-fee business checking and business money market accounts. The company operates through four reportable segments Banking, Alternative Lending, NSBF and Payments.

About CLLS Cellectis S.A.

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Share on Social Networks: